Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification

Published:2024-06-03 Issue:1 Volume:15 Page:355-359
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Patel Jai N.¹²,Singh Jai³,Ghosh Nilanjan²⁴

Affiliation:

1. Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA

2. Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA

3. Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC 28204, USA

4. Department of Hematologic Malignancies and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA

Publisher

Impact Journals, LLC

Reference22 articles.

1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia;Devereux;N Engl J Med,2015

2. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis;Goy;Haematologica,2018

3. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis;Pinto;PLoS One,2019

4. Cardiovascular Adverse Effects of Novel Bruton Tyrosine Kinase Inhibitors: What All Cardiologists Should Know;Copeland-Halperin;Am Coll Cardiol,2023

5. Ibrutinib and atrial fibrillation as cardiotoxicity - A new safety warning that impacts overall survival;Gopal;Int J Mol Immuno Oncol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP